444 related articles for article (PubMed ID: 30442766)
1. LZTR1 is a regulator of RAS ubiquitination and signaling.
Bigenzahn JW; Collu GM; Kartnig F; Pieraks M; Vladimer GI; Heinz LX; Sedlyarov V; Schischlik F; Fauster A; Rebsamen M; Parapatics K; Blomen VA; Müller AC; Winter GE; Kralovics R; Brummelkamp TR; Mlodzik M; Superti-Furga G
Science; 2018 Dec; 362(6419):1171-1177. PubMed ID: 30442766
[TBL] [Abstract][Full Text] [Related]
2. Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
Chen S; Vedula RS; Cuevas-Navarro A; Lu B; Hogg SJ; Wang E; Benbarche S; Knorr K; Kim WJ; Stanley RF; Cho H; Erickson C; Singer M; Cui D; Tittley S; Durham BH; Pavletich TS; Fiala E; Walsh MF; Inoue D; Monette S; Taylor J; Rosen N; McCormick F; Lindsley RC; Castel P; Abdel-Wahab O
Cancer Discov; 2022 Oct; 12(10):2434-2453. PubMed ID: 35904492
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
4. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.
Steklov M; Pandolfi S; Baietti MF; Batiuk A; Carai P; Najm P; Zhang M; Jang H; Renzi F; Cai Y; Abbasi Asbagh L; Pastor T; De Troyer M; Simicek M; Radaelli E; Brems H; Legius E; Tavernier J; Gevaert K; Impens F; Messiaen L; Nussinov R; Heymans S; Eyckerman S; Sablina AA
Science; 2018 Dec; 362(6419):1177-1182. PubMed ID: 30442762
[TBL] [Abstract][Full Text] [Related]
5. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
[TBL] [Abstract][Full Text] [Related]
6. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Melge AR; Kumar LG; K P; Nair SV; K M; C GM
J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
9. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
10. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
12. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
13. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
15. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
16. LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.
Abe T; Umeki I; Kanno SI; Inoue SI; Niihori T; Aoki Y
Cell Death Differ; 2020 Mar; 27(3):1023-1035. PubMed ID: 31337872
[TBL] [Abstract][Full Text] [Related]
17. Ariad Pharmaceutical's ninja cancer drug inhibits armies of mutants.
Wolfson W
Chem Biol; 2012 Sep; 19(9):1075-6. PubMed ID: 22999871
[No Abstract] [Full Text] [Related]
18. Structure, function, and resistance in chronic myeloid leukemia.
Radich J
Cancer Cell; 2014 Sep; 26(3):305-306. PubMed ID: 25203318
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
20. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
